Nutrition Guidance During GLP-1 Treatment: Evidence-Based Approaches
How to counsel patients on nutrition during GLP-1 treatment — managing reduced appetite, preventing muscle loss, and building sustainable habits.
One of the most underappreciated aspects of GLP-1 prescribing is nutritional guidance. The medications work — patients eat less, lose weight, and see metabolic improvements. But without appropriate dietary counselling, that weight loss can come at a cost: muscle wasting, micronutrient deficiencies, and eating patterns that are unsustainable once treatment ends.
For prescribers, integrating evidence-based nutrition advice into your GLP-1 service is not optional. It is essential for good clinical outcomes and long-term patient success.
The Appetite Suppression Challenge
GLP-1 receptor agonists reduce appetite through multiple mechanisms — delayed gastric emptying, central satiety signalling, and reduced food reward. For patients, this often manifests as a profound disinterest in eating. Many describe it as simply forgetting to eat, or finding that food they once enjoyed now holds no appeal.
While this appetite suppression drives weight loss, it also creates a nutritional challenge. Patients who are eating 800 to 1,000 calories per day — common in the early weeks of treatment — are unlikely to meet their protein, vitamin, and mineral requirements without conscious effort. Left to their own devices, many patients default to whatever is most convenient: a slice of toast here, a few bites of dinner there.
This is where prescriber guidance makes a real difference. Patients need to understand that while they may not feel hungry, their body still requires adequate nutrition — and that the quality of what they eat matters more than ever when the quantity drops.
Protein: The Non-Negotiable Priority
The single most important nutritional message for GLP-1 patients is protein prioritisation. The STEP trials and subsequent real-world data have consistently shown that a significant proportion of GLP-1-associated weight loss comes from lean mass — muscle and bone — rather than fat alone. Some analyses suggest that lean mass accounts for 25 to 40 per cent of total weight lost without dietary intervention.
This matters clinically. Muscle loss reduces metabolic rate (making weight regain more likely), impairs functional capacity (particularly in older patients), and is associated with poorer long-term health outcomes.
The evidence supports a protein intake of 1.2 to 1.6 grams per kilogram of body weight per day for patients on GLP-1 therapy. For a 90kg patient, that translates to roughly 110 to 145 grams of protein daily — a challenging target when appetite is significantly reduced.
Practical advice helps: eat protein first at every meal, keep high-protein snacks accessible (Greek yoghurt, cottage cheese, protein drinks), and consider a protein supplement if whole food intake is consistently low. The key is making this guidance specific and repeatable, not a one-off mention during an initial consultation.
Hydration: An Overlooked Risk
GLP-1 medications increase the risk of dehydration through several pathways. Reduced food intake means less water from food sources. Nausea and occasional vomiting deplete fluids directly. And delayed gastric emptying can make patients feel uncomfortably full when drinking, leading them to drink less.
Dehydration is more than a comfort issue. It can cause constipation (already a common GLP-1 side effect), headaches, dizziness, and in severe cases, acute kidney injury. Patients on concurrent medications such as metformin or antihypertensives may be at particular risk.
A simple target of 2 to 2.5 litres of fluid per day, with a reminder that sipping throughout the day is better than large volumes at once, should be part of every patient’s care plan. Monitoring hydration through daily check-ins can help identify patients who are consistently falling short before clinical consequences develop.
Meal Timing and Injection Cycles
Patients often ask whether they should eat differently on injection day compared to other days. While there is no rigid protocol, practical experience suggests that eating a lighter meal before the injection and avoiding large or high-fat meals for 24 hours afterwards can reduce nausea.
As the week progresses and the medication’s peak effect subsides (typically days three to five for tirzepatide), appetite begins to return slightly. This is often the best window for patients to focus on higher-protein, nutrient-dense meals. Helping patients understand their own weekly appetite cycle — and plan their eating accordingly — is a simple but effective intervention.
Fibre and Gastrointestinal Management
Constipation is one of the most common side effects of GLP-1 treatment, reported by up to 20 per cent of patients on tirzepatide. The natural instinct is to increase fibre intake, but this requires careful guidance. Adding large amounts of insoluble fibre to an already slow-moving gut can worsen bloating and discomfort.
A gradual increase in soluble fibre (oats, flaxseed, psyllium husk) combined with adequate hydration is generally better tolerated. Patients should also be advised that if constipation persists beyond a week, pharmacological management (such as an osmotic laxative) may be appropriate — they should not simply endure it.
Similarly, patients experiencing nausea should be advised to avoid overly fatty, spicy, or rich foods, particularly in the first few days after injection. Small, frequent meals tend to be better tolerated than three large ones.
When to Refer to a Dietitian
Most nutritional guidance during GLP-1 treatment can be delivered by prescribers with appropriate knowledge. However, certain patients benefit from specialist dietetic input: those with eating disorder histories, patients with complex comorbidities (type 2 diabetes, coeliac disease, renal impairment), and patients who are losing weight too rapidly or showing signs of malnutrition.
Having a clear referral pathway to a registered dietitian — and knowing when to use it — is an important part of a comprehensive GLP-1 service.
Reinforcing Nutritional Messages Over Time
The challenge with nutritional guidance is that a single conversation during the initial consultation is rarely sufficient. Patients are overwhelmed with information at the start of treatment, and dietary advice is often the first thing forgotten.
Effective nutrition support requires repetition and reinforcement — ideally integrated into the regular rhythm of patient monitoring. When a patient reports increased nausea through a daily check-in, that is a natural moment to reinforce meal timing advice. When weight loss accelerates, it is an opportunity to revisit protein targets.
This is where structured digital support adds genuine clinical value. Automated prompts, tailored educational content, and regular touchpoints ensure that nutritional messaging is consistent and timely, without requiring a clinician to manually deliver it at every interaction.
Building nutrition into the fabric of your GLP-1 service — rather than treating it as an afterthought — improves outcomes, reduces side effects, and gives patients the tools to maintain their progress long after treatment ends. If you would like to see how Cadence helps prescribers deliver this kind of integrated support, book a demo to learn more.